Given that chronic subclinicalinflammation is important in atherosclerosis and restenosis after PCI,inhibiting the proinflammatory adhesion molecule sICAM-1 and CRP levels by rosiglitazone,might have potentially beneficial effects in type 2 diabetic patients with CAD. Here, CRP is linked to atherosclerosis.